obesity therapies

Sep 02, 2025

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

May 12, 2025

9 Promising Obesity Drugs Set to Launch by 2030

Mar 26, 2025

The Latest Breakthroughs in Obesity Treatment: A New Era of Weight Loss Innovation

Mar 14, 2025

Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?

Mar 12, 2025

The Race to Redefine Obesity Treatment

Mar 12, 2025

8 Emerging Obesity Trends Transforming Therapeutics Segment

Jul 03, 2023

Eli Lilly’s Obesity Treatment Drug Candidates – A Show for the Competitors

Newsletter/Whitepaper